Stimulating the release of incretin hormones might therefore be a rational potential therapeutic strategy in Type 2 diabetes, provided that the entero-endocrine axis is not severely impaired by ongoing poor glycaemic control. Here, GIP is linked to type 2 diabetes mellitus.